FDA approves gene therapy for genetic hearing loss amid systemic gaps in equitable healthcare access and indigenous genetic sovereignty debates

Indigenous communities have long-standing knowledge systems addressing hearing loss through traditional medicine, dietary practices, and communal care models that prioritise holistic well-being over individualised interventions. However, these perspectives are systematically excluded from mainstream biomedical research, which privileges patentable, high-tech solutions over culturally grounded alternatives. The erasure of Indigenous genetic sovereignty—such as the right to control biological data derived from Indigenous peoples—further marginalises these communities in the narrative of genetic innovation. Without integrating Indigenous knowledge, gene therapies risk reinforcing colonial patterns of exploitation rather than fostering equitable healthcare.

The history of genetic research is marred by exploitation, from the unethical Tuskegee Syphilis Study to the HeLa cell line controversy, where Henrietta Lacks’ cells were taken without consent and commercialised. The Havasupai Tribe case in the 1990s revealed how Indigenous DNA samples were used for unrelated research without informed consent, leading to legal battles over genetic data ownership. These precedents underscore the need for ethical safeguards in genetic therapies, yet the current narrative frames Regeneron’s approval as a triumph of progress without acknowledging these systemic failures. The lack of historical reflection risks repeating past injustices in the name of medical advancement.

Cross-culturally, hearing loss is addressed through diverse frameworks: in Traditional Chinese Medicine, it may be linked to kidney energy imbalances and treated with acupuncture or herbal remedies, while in African traditions, it is sometimes addressed through community-based healing rituals. Western biomedical models, however, often prioritise technological interventions like gene therapy without considering these alternative approaches. This cultural disconnect highlights the need for integrative healthcare models that bridge traditional and modern medicine, ensuring solutions are both scientifically rigorous and culturally resonant. The absence of such dialogue in mainstream coverage limits the potential for truly inclusive healthcare innovation.

Scientifically, the FDA’s approval of Regeneron’s gene therapy for genetic hearing loss is based on clinical trial data demonstrating safety and efficacy in a subset of patients with a specific genetic mutation (OTOF). However, the trials may not fully represent diverse populations, as genetic variations across ethnic groups can affect treatment outcomes. Additionally, the long-term effects of gene therapy remain uncertain, and the high cost of such therapies raises questions about scalability and accessibility. The scientific narrative must also consider the ethical implications of germline editing, which could have unintended consequences for future generations.

Artistically and spiritually, hearing loss has been a recurring theme in literature, music, and visual arts, often symbolising isolation, communication barriers, or the struggle for connection. For instance, Beethoven’s deafness shaped his compositions, illustrating how sensory limitations can fuel creative expression. In many spiritual traditions, hearing loss is framed as a test of resilience or a call to deeper introspection, rather than a purely medical condition. These perspectives challenge the biomedical reductionism of gene therapy, suggesting that healing must address emotional and spiritual dimensions as well as physical ones. The absence of such holistic frameworks in mainstream coverage limits the potential for truly transformative healthcare solutions.

Future modelling of gene therapy for hearing loss must account for ethical, economic, and equity considerations to avoid repeating past mistakes in medical innovation. Scenario planning should explore the potential for open-source genetic therapies to democratise access, as well as the risks of corporate monopolies on biological data. Additionally, future healthcare systems must integrate genetic therapies with public health infrastructure to ensure equitable distribution, particularly in low-resource settings. Without addressing these structural barriers, gene therapies risk becoming another example of 'innovation for the few' rather than a systemic solution for all.

Marginalised voices—including Indigenous communities, low-income populations, and people with disabilities—are systematically excluded from the narrative of genetic innovation, despite bearing the brunt of its ethical and economic consequences. For example, Indigenous peoples have historically been subjected to unethical genetic research, and their exclusion from clinical trials perpetuates disparities in healthcare outcomes. Additionally, the high cost of gene therapies means that marginalised communities may never benefit from these advancements, further entrenching health inequities. The framing of gene therapy as a universal solution ignores these power imbalances and the need for participatory, community-driven healthcare models.